Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$14B
P/E
N/A
Revenue Growth
+15.0%
Gross Margin
N/A
ROE
N/A
About Exact Sciences
Listed on the NASDAQ, Exact Sciences operates as a mid-cap player in the healthcare sector, offering investors focused access to biotech and genomics growth drivers. Cancer screening pioneer with Cologuard and liquid biopsy development. With a $14B market capitalization and no current profitability, the business is characterized by consistent top-line gains, reporting +15% revenue change year-over-year.
Expert Coverage
Unlock Full EXAS Analysis
Expert analysis and coverage for Exact Sciences
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Regeneron Pharmaceuticals
Biotech powerhouse with strong antibody pipeline and Dupixent franchise.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.